Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives
January 11, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
Recce Pharmaceuticals Establishes Anti-Infective Research Unit at Murdoch Children’s Research Institute
December 19, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Recce’s new Anti-Infective Research Unit located within Murdoch Children's world-leading research facilities – internationally recognized for medical research breakthroughsFit-for-purpose...
Recce Pharmaceuticals Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE® 327 in Patients with Diabetic Foot Infections
December 12, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Phase 1/2 trial of RECCE® 327 (R327) is approved to start at the South West Sydney Limb Preservation and Wound Research Unit, located at the Ingham Institute of Medical ResearchStudy will...
Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update
October 18, 2022 08:11 ET
|
Recce Pharmaceuticals
Highlights: RECCE® 327 (R327) was shown to significantly reduce SARS-CoV-2 levels in hamsters, the gold-standard in COVID-19 preclinical animal modelsNew patents lodged supporting anti-infective...
Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs
October 03, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Phase 1 safety and tolerability study of RECCE® 327 (R327) advancing to a Phase 1b/2a multi-dose and sepsis efficacy studyInitiating two new Phase 2 trials of R327 for the treatment of...
Recce Pharmaceuticals Appoints Alistair McKeough to its Board of Directors
September 07, 2022 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company) is pleased to announce the appointment of Alistair McKeough to its Board of...
Recce Pharmaceuticals Announces Positive Safety Data from Seventh Cohort of Phase 1 Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
August 23, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: 10 subjects in cohort seven were intravenously dosed with RECCE® 327 at 6,000mg Independent Safety Committee reviewing cohort seven data and anticipate a recommendation to proceed to...
Recce Pharmaceuticals Appoints Philip Sutton, Ph.D., as Vice President of Translational Sciences
July 12, 2022 08:00 ET
|
Recce Pharmaceuticals
– Dr. Sutton to help advance Recce’s portfolio of infectious disease programs focused on significant unmet medical needs – SYDNEY Australia, July 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals...
Recce Pharmaceuticals Announces Positive Safety Data from Sixth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
June 22, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: 10 subjects in cohort six intravenously dosed with RECCE® 327 at 4,000mg demonstrated good safety and tolerabilityIndependent Safety Committee to review cohort six data – anticipate...
Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg
May 23, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mgIndependent Safety Committee approves cohort six dosing at 4,000mg;...